Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago, emphasizes the importance of patient education and caregiver involvement in managing complex therapies and advises oncologists to confidently integrate advanced treatments.
Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago (UIC), emphasizes the importance of patient education and caregiver support in navigating complex therapies like transplants, while advising oncologists to embrace innovative treatments such as bispecific antibodies and chimeric antigen receptor T-cell (CAR T) therapy for multiple myeloma, tailoring them to patients' frailty levels.
Sanchez participated in a panel discussion on best practices in multiple myeloma care at a recent Institute for Value-Based Medicine® event in Chicago.
This transcript has been lightly edited for clarity.
Transcript
What role does patient education play in managing expectations and outcomes, especially with the increased use of innovative but complex therapies?
Education is crucial in terms of supportive care. I'm from the transplant world, so that's where we really need to make sure the patient has a caregiver or has someone who can help them navigate the system and help them with the chores. Usually with our patient population that we take care at UIC, we try to always make sure the patient has someone who can help navigate everything, the whole transplant or chemotherapy process, everything. I think it's the most important thing. And it's a team, so our nurses do a great job there, too.
What advice would you give to other oncologists who are looking to adopt more value-based approaches to managing multiple myeloma?
My advice would be to, first, use the most effective therapies for myeloma that you have up front, and don't be afraid to use the new therapies that are available, especially the bispecifics and CAR T. We can select the patients who are the best patients to whom we can give those treatments. Make sure patients are not very frail or ultra frail; we can adapt those treatments according to their frailty status. But don't be afraid either to use them. Because these are all new treatments that make us anxious and make us go, "What are we going to do if the patient gets a fever?"—all those things, yeah— but don't be afraid to try to use targeted therapies in the right patient.
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
Legal Navigation Services Key to Addressing Disparities in Cancer Care
July 31st 2025A significant number of patients with cancer, caregivers, and health care professionals face significant disparities in legal issues, with the most common needs revolving around health insurance, finances, employment, and disability insurance.
Read More